Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEN-HOST: Therapeutics for Moderate or Severe Dengue
NCT07543458Phase 3Not yet recruiting
- Sponsor
- Oxford University Clinical Research Unit
- Start
- Oct 2026
- Primary completion
- Jul 2030
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Antibody-Based Therapeutics
- Countries
- 10
01
Overview
A Phase 3 trial of baricitinib, dexamethasone, acetylcysteine in dengue fever, sponsored by Oxford University Clinical Research Unit. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
baricitinibdexamethasoneacetylcysteine
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT07543458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07543458.